Abstract 4481
Background
Combining Cetuximab with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with RAS wild type (RAS-wt) locally advanced or metastatic colorectal cancer (mCRC). Therefore, this active treatment excludes 60% of patients (pts) with muted primary tumor. We tested in this pilot study Cetuximab-based therapy in pts with RAS-wt in plasma whose primaries were RAS muted (RAS-mt).
Methods
We analysed KRAS, NRAS, BRAF and PI3KCA mutations in plasma using a new and ultra-sensitive analysis based on mass spectrometry detection (MassARRAY System with Ultra SEEK technology; detection of 0.1% muted alleles) in pts with histological confirmed RAS-mt mCRC after consent. Pts with plasma RAS-wt whose diseases were progressive received Cetuximab-FOLFIRI while plasma RAS-mt pts received investigator’s proposal therapies.
Results
Sixteen pts were registered in three centers. There were 11 males (69%) and 5 females (31%) aged 48 to 81 years (median, 69) with unresectable metastatic adenocarcinoma from colon cancer (9 pts, 56%) and rectum cancer (7 pts, 44%). They had a median of 2 metastatic sites (1 to 4) and had previously received 1 to 4 chemotherapy lines (median, 3). Plasma genotyping showed RAS-mt in 7 patients (44%) and RAS-wt in 9 patients (56%). The 9 pts with plasma RAS-wt received 1 to 16 courses of Cetuximab-FOLFIRI (median, 6). We observed as best response, 1 complete response, 3 partial responses, and 1 progressive disease. Three pts were not assessed yet for efficacy. No grade 3-4 toxicity was encountered. At the cut-off time on 2019.04.23, median follow-up was 5.3 months (0.3 to 19.5). Survival rate were 77.8% (7/9) and 28.6% (2/7) for pts with RAS-wt and RAS-mt respectively. Median overall survival was not reached for pts with RAS-wt whereas it was 4.7 months [95%CL, 0.0-9.6] for RAS-mt pts, p (Log Rank)=0.001.
Conclusions
Our finding suggests that pts with RAS-mt mCRC whose plasma biopsies are RAS-wt could benefit from cetuximab-based therapy. As a result to these preliminary data, we have planned a phase II study targeting the plasma RAS-wt with EGFR inhibitors in first line mCRC.
Clinical trial identification
Editorial acknowledgement
AK-SCIENCE, Vitry-Sur-Seine, France.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3034 - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL STUDY
Presenter: Maria Agnese Fabbri
Session: Poster Display session 2
Resources:
Abstract
4772 - Real world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy
Presenter: Maysa Vilbert
Session: Poster Display session 2
Resources:
Abstract
5627 - Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals
Presenter: Sabela Recalde
Session: Poster Display session 2
Resources:
Abstract
3917 - Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients
Presenter: Mariana Chavez Mac Gregor
Session: Poster Display session 2
Resources:
Abstract
2246 - Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients With Breast Cancer
Presenter: Laura Spring
Session: Poster Display session 2
Resources:
Abstract
581 - The rationale for the effectiveness of systemic treatment of breast cancer depending on the body weight index
Presenter: Mohammad Hojouj
Session: Poster Display session 2
Resources:
Abstract
5327 - Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
Presenter: Silvia Mihaela Ilie
Session: Poster Display session 2
Resources:
Abstract
3613 - Pre-specified interim analysis of the SAFE trial (NCT2236806): a 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab.
Presenter: Lorenzo Livi
Session: Poster Display session 2
Resources:
Abstract
3736 - Safety of hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-center comparative study.
Presenter: Icro Meattini
Session: Poster Display session 2
Resources:
Abstract
5085 - Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab
Presenter: Isabel Blancas López-Barajas
Session: Poster Display session 2
Resources:
Abstract